Skip to content
MARKETS / NASDAQ / VVOS
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Vivos Therapeutics, Inc. VVOS

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$17.4M
▲ 16.0% YoY
$-21.2M
$-17.6M
Growth
USD 17.4M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 17.4 · Net income -21.2
8M16M-8M-16M2019202020212022202320242025
Compound annual growth
+2.9%
+5.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +5.9% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−122 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -114.1% · Net -121.7%
-50%-100%-150%2019202020212022202320242025
ROE
FY2025 · ROE -655.0%
-200%-400%-600%2019202020212022202320242025

Each USD of equity lost 655 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -17.6
-8M-16M2019202020212022202320242025

Total assetsUSD 25.2M
EquityUSD -1.5M
CashUSD 2.0M
Gross debtUSD 8.8M
Net debtUSD 6.8M
Current ratio0.24×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B0.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B·······
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−2.07−2.22−11.14−25.90−0.96−1.40−0.95
Dividend / sh $·······
Payout %·······
ROE %−655.0−266.3−521.2−157.2−95.6−172.6·
Shares out B0.010.010.000.000.020.020.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 35 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 60 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019

Share this section

Download image